Fair Value Calculator Fair Value Calculator
EN DE

Dynamic solution Co (290660) Fair Value & Analysis

Healthcare · KR · Market cap 47.4B KRW

DS Dynamic solution Co 290660 · KQ
Price1,689 KRW
Fair Value304.96 KRW
Upside-81.9%
Quality41/100
Watch Dynamic solution Co for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 201.28 KRW – 381.20 KRW

Fair value as of: Jul 7, 2026

From 1 valuation models · updated today

Fair value updated Jul 7, 2026 — revised from 4,754 KRW to 304.96 KRW (−93.6%) since Jun 24, 2026. Share price +96.4% over the past month.

Price vs Fair Value (12 months)

1,983 KRW 664.00 KRW Fair Value 304.96 KRW May 2025 Jul 2026

12‑month range 664.00 KRW – 1,983 KRW · fair‑value band 201.28 KRW – 381.20 KRW · the 1,689 KRW price screens above the 304.96 KRW fair value. As of Jul 7, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Dynamic solution Co (290660) currently trades at 1,689 KRW, while our model-based Fair Value estimate is 304.96 KRW — implying the stock looks roughly 81.9% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 15.5B KRW. Revenue declined 16.0% year over year. It earns a return on equity of -31.9%. Net debt stands at 3.2B KRW. Fundamentals as of Jul 7, 2026

Our scenario range runs from 201.28 KRW (bear case) to 381.20 KRW (bull case); at 1,689 KRW, the current price sits above that range. The share trades about 12% below its 52-week high and 164% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside — at -82%, 290660 screens richer than that median.

Key figures & financial health

Revenue (TTM) 15.5B KRW
Revenue growth (YoY) -16.0%
Net margin -103%
Return on equity -31.9%
Free cash flow −2.4B KRW FY2025
Operating margin -98.2%
More key figures
EPS growth (YoY) +87,737%
Net debt 3.2B KRW FY2023

Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.

About the company

Dynamic solution Co.,Ltd. researches, develops, manufactures, and sells rehabilitation medical devices and contents for stroke and spinal cord injuries. The company offers Neofect Smart Glove, a high-tech rehab device that measures movements of the forearm, wrist, and digits with accelerometer and bending sensors; Neofect Smart Kids for hand rehabilitation in children; Neofect Smart Board, a high-tech medical device that develops users' shoulder and upper arm movements to promote improved functional reach and muscle control; Neofect Smart Balance to practice balance and posture during real-world training scenarios; and Neofect Smart Pegboard, a digital pegboard for functional and cognitive rehabilitation. It also provides Neofect Smart Table for dementia prevention and rehabilitation program; Neomano, a wearable robotic glove; Neofect Comcog, a cognitive rehabilitation program that helps patients with stroke, dementia, traumatic brain injury, brain tumor, and cerebral palsy; and …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Dynamic solution Co reported revenue of 16.1B KRW in FY2025 versus 23.2B KRW in FY2021, a compound −8.8%/yr. Reported net income was −12.3B KRW in FY2025.

Revenue −8.8%/yr
FY21 23.2B KRW
FY22 26.2B KRW
FY23 26.6B KRW
FY24 21.1B KRW
FY25 16.1B KRW
Net income
FY21 −5.0B KRW
FY22 −9.6B KRW
FY23 −5.0B KRW
FY24 −951M KRW
FY25 −12.3B KRW

Is 290660 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Dynamic solution Co Fair Value". https://www.fairvalue-calculator.com/stock/290660

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABTT34 R$38.22 R$30.39 -20%
Stryker Corporation S1YK34 R$77.83 R$8.47 -89%
Medtronic plc MDTC34 R$211.05 R$29.52 -86%
Boston Scientific Corporation B1SX34 R$248.75 R$221.81 -11%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%
Siemens Healthineers AG SEMHF $40.29 $47.96 +19%
GE HealthCare Technologies Inc GEHC $63.76 $44.97 -29%
DexCom, Inc DXCM $69.07 $65.56 -5%
Koninklijke Philips N.V 1PHIA €24.31 €9.97 -59%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥141.85 ¥147.63 +4%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Dynamic solution Co (290660) undervalued?
As of Jul 7, 2026, our model estimates a fair value of 304.96 KRW versus a price of 1,689 KRW — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 290660?
Our model-based fair value for Dynamic solution Co is 304.96 KRW (as of Jul 7, 2026), built from audited fundamentals. The current price is 1,689 KRW.
What is the quality score of 290660?
Dynamic solution Co has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Dynamic solution Co (290660)?
Dynamic solution Co reported trailing-twelve-month revenue of about 15.5B KRW (latest available figure, as of Jul 7, 2026).
What is the net profit margin of 290660?
The net profit margin of Dynamic solution Co is about -102.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.